Genocea Biosciences, Inc. (GNCA): Jonathan Poole , CFO of Genocea Biosciences, Inc. purchased 4,000 shares on May 9, 2016. The Insider buying transaction was reported by the company on May 10, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.88 per share for a total value of $15,520.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Dec 16, 2015, William D Clark (CEO) purchased 3,800 shares at $6.45 per share price.On Sep 3, 2015, Jessica Baker Flechtner (Sr. VP of Research) sold 2,229 shares at $11.35 per share price.Also, On Mar 17, 2015, Stephen J Hoffman (director) purchased 700,000 shares at $8.25 per share price.
Shares of Genocea Biosciences Inc (GNCA) ended Friday, May 6, 2016 session in red amid volatile trading. The shares closed down -0.21 points or -5.41% at $3.67 with 7,05,757 shares getting traded. Post opening the session at $3.89, the shares hit an intraday low of $3.495 and an intraday high of $3.9 and the price vacillated in this range throughout the day. The company has a market cap of $103 M and the number of outstanding shares has been calculated to be 2,81,52,589 shares. The 52-week high of Genocea Biosciences Inc is $16.18 and the 52-week low is $2.56.
Company has been under the radar of several Street Analysts.Genocea Biosciences Inc is Reiterated by Stifel to Buy and the brokerage firm has raised the Price Target to $ 13 from a previous price target of $11 .The Rating was issued on Apr 1, 2016.
Genocea Biosciences Inc. is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies to address diseases with unmet needs. It uses its discovery platform AnTigen Lead Acquisition System (ATLAS) to design vaccines and immunotherapies that act in part through T cell (or cellular) immune responses in contrast to approved vaccines and immunotherapies which are designed to act primarily through B cell (or antibody) immune responses. It has two product candidates in Phase II clinical development: GEN-003 and GEN-004. It also has product candidates which are GEN-001 GEN-002 and GEN-005 in pre-clinical development for diseases including genital herpes chlamydia and malaria. It also creates a library of every protein in the proteome of the pathogen of interest. It uses ATLAS as a throughput engine to screen human T cells to identify relevant T cell vaccine antigens.